New and improved strategies for the treatment of gout

References

• ChoiHKMountDBReginatoAMPathogenesis of goutAnn Intern Med2005143749951616204163
   PubMed Web of Science ®Google Scholar
• ChoiHKCurhanGGout: epidemiology and lifestyle choicesCurr Opin Rheumatol200517334134515838248
   PubMed Web of Science ®Google Scholar
• NriaguJOSaturnine gout among Roman aristocrats. Did lead poisoning contribute to the fall of the Empire?N Engl J Med1983308116606636338384
   PubMed Web of Science ®Google Scholar
• HealeyLAPort wine and the goutArthritis Rheum197518Suppl 66596621106430
   PubMed Web of Science ®Google Scholar
• SteinbockRTLead ingestion in historyN Engl J Med19793015277377079
   PubMed Web of Science ®Google Scholar
• HakAEChoiHKLifestyle and goutCurr Opin Rheumatol200820217918618349748
   PubMed Web of Science ®Google Scholar
• SaagKGChoiHEpidemiology, risk factors, and lifestyle modifications for goutArthritis Res Ther20068Suppl 1S216820041
   PubMed Web of Science ®Google Scholar
• SaagKGMikulsTRRecent advances in the epidemiology of goutCurr Rheumatol Rep20057323524115919001
   PubMedGoogle Scholar
• KahnAMEffect of diuretics on the renal handling of urateSemin Nephrol1988833053143059433
   PubMed Web of Science ®Google Scholar
• CaspiDLubartEGraffEHabotBYaronMSegalRThe effect of mini-dose aspirin on renal function and uric acid handling in elderly patientsArthritis Rheum200043110310810643705
   PubMed Web of Science ®Google Scholar
• SchumacherHRJrBeckerMAWortmannRLEffects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trialArthritis Rheum200859111540154818975369
   PubMed Web of Science ®Google Scholar
• SundyJSBeckerMABarafHSReduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: Results of a phase II randomized studyArthritis Rheum20085892882289118759308
   PubMed Web of Science ®Google Scholar
• ShermanMRSaiferMGPerez-RuizFPEG-uricase in the management of treatment-resistant gout and hyperuricemiaAdv Drug Deliv Rev2008601596817826865
   PubMed Web of Science ®Google Scholar
• FarkouhMEGreenbergBPAn evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugsAm J Cardiol200910391227123719406264
   PubMed Web of Science ®Google Scholar
• EdwardsNLThe role of hyperuricemia and gout in kidney and cardiovascular diseaseCleve Clin J Med200875Suppl 5S13S1618822470
   PubMedGoogle Scholar
• FeigDIKangDHJohnsonRJUric acid and cardiovascular riskN Engl J Med2008359171811182118946066
   PubMed Web of Science ®Google Scholar
• SchlesingerNDalbethNPerez-RuizFGout – what are the treatment options?Expert Opin Pharmacother20091081319132819463070
   PubMed Web of Science ®Google Scholar
• ThieleRGSchlesingerNUltrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achievedRheumatol Int201030449550319543895
   PubMed Web of Science ®Google Scholar
• Perez-RuizFDalbethNUrresolaAde MiguelESchlesingerNGout. Imaging of gout: findings and utilityArthritis Res Ther200911323219591633
   PubMed Web of Science ®Google Scholar
• LeeSJHirschJDTerkeltaubRPerceptions of disease and health-related quality of life among patients with goutRheumatology (Oxford)200948558258619307257
   PubMed Web of Science ®Google Scholar
• SinghJAQuality of life and quality of care for patients with goutCurr Rheumatol Rep200911215416019296889
   PubMedGoogle Scholar
• SinghJAStrandVGout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veteransAnn Rheum Dis20086791310131618178692
   PubMed Web of Science ®Google Scholar
• RoddyEZhangWDohertyMIs gout associated with reduced quality of life? A case-control studyRheumatology (Oxford)20074691441144417586863
   PubMed Web of Science ®Google Scholar
• WinzenbergTBuchbinderRCochrane Musculoskeletal Group review: acute goutSteroids or NSAIDs? Let this overview from the Cochrane Group help you decide what’s best for your patientJ Fam Pract2009587E1E419607767
   PubMedGoogle Scholar
• KimSYChoiHKGout and quality of lifeJ Rheumatol200936586586819435969
   PubMed Web of Science ®Google Scholar
• ShultenPThomasJMillerMSmithMAhernMThe role of diet in the management of gout: a comparison of knowledge and attitudes to current evidenceJ Hum Nutr Diet200922131119192022
   PubMed Web of Science ®Google Scholar
• WeaverALEpidemiology of goutCleve Clin J Med200875Suppl 5S9S1218819329
   PubMedGoogle Scholar
• CampionEWGlynnRJDeLabryLOAsymptomatic hyperuricemia. Risks and consequences in the Normative Aging StudyAm J Med198738234214263826098
   PubMedGoogle Scholar
• MarinelloERiario-SforzaGMarcolongoRPlasma follicle-stimulating hormone, luteinizing hormone, and sex hormones in patients with goutArthritis Rheum19852821271313918542
   PubMed Web of Science ®Google Scholar
• RosenRTomerYCarelRWeinbergerASerum 17-beta-estradiol and testosterone levels in asymptomatic hyperuricaemic menClin Rheumatol19941322192238088062
   PubMed Web of Science ®Google Scholar
• RhoYHChoiSJLeeYHThe prevalence of metabolic syndrome in patients with gout: a multicenter studyJ Korean Med Sci20052061029103316361817
   PubMed Web of Science ®Google Scholar
• OnatAUyarelHHergencGSerum uric acid is a determinant of metabolic syndrome in a population-based studyAm J Hypertens200619101055106217027827
   PubMed Web of Science ®Google Scholar
• TakahashiSYamamotoTMoriwakiYTsutsumiZHigashinoKImpaired lipoprotein metabolism in patients with primary gout – influence of alcohol intake and body weightBr J Rheumatol19943387317348055199
   PubMedGoogle Scholar
• GenelhuVACeloriaBMDuarteSFCabelloPHFrancischettiEANot all obese subjects of multiethnic origin are at similar risk for developing hypertension and type 2 diabetesEur J Intern Med200920328929519393496
   PubMed Web of Science ®Google Scholar
• ChoiHKDiet, alcohol, and gout: how do we advise patients given recent developments?Curr Rheumatol Rep20057322022615918999
   PubMedGoogle Scholar
• TorralbaTPBayani-SiosonPSThe Filipino and goutSemin Arthritis Rheum1975443073201135632
   PubMedGoogle Scholar
• KaplanHKlatskinGSarcoidosis, psoriasis, and gout: syndrome or coincidence?Yale J Biol Med19603233535214404387
   PubMedGoogle Scholar
• YuTFSecondary gout associated with myeloproliferative diseasesArthritis Rheum1965857657715216775
   PubMedGoogle Scholar
• BrutscheRLDoernerAAChronic lymphocytic leukemia; report of a case with marked uric acid crystalluriaAMA Arch Intern Med195697681781913312727
   PubMedGoogle Scholar
• LudwigGDSaturnine gout; a secondary type of goutAMA Arch Intern Med1957100580281213468828
   PubMedGoogle Scholar
• KangEHLeeEYLeeYJSongYWLeeEBClinical features and risk factors of postsurgical goutAnn Rheum Dis20086791271127517998214
   PubMed Web of Science ®Google Scholar
• RajJMSudhakarSSemsKCarlsonRWArthritis in the intensive care unitCrit Care Clin200218476778012418440
   PubMed Web of Science ®Google Scholar
• KurtzmanNACoexistent sarcoidosis and goutJ Lancet19658519519614290322
   PubMedGoogle Scholar
• RubinMRSilverbergSJRheumatic manifestations of primary hyperparathyroidism and parathyroid hormone therapyCurr Rheumatol Rep20024217918511890884
   PubMedGoogle Scholar
• KangHCChungDEKimDWKimHDEarly- and late-onset complications of the ketogenic diet for intractable epilepsyEpilepsia20044591116112315329077
   PubMed Web of Science ®Google Scholar
• CameronJSSimmondsHAHereditary hyperuricemia and renal diseaseSemin Nephrol200525191815660329
   PubMed Web of Science ®Google Scholar
• KamataniNYamanakaHTotokawaSKashiwazakiSHigurashiMDown syndrome with coexistent gout: report of six patients and possible reasons for the scarcity of descriptions of this associationAnn Rheum Dis19965596496508882140
   PubMed Web of Science ®Google Scholar
• SaigalRChakrabortyAYadavRNPrashantRKPartial HPRT deficiency (Kelley-Seegmiller syndrome)J Assoc Physicians India200654495216649740
   PubMedGoogle Scholar
• NyhanWLInherited hyperuricemic disordersContrib Nephrol2005147223415604603
   PubMed Web of Science ®Google Scholar
• NakagawaTHuHZharikovSA causal role for uric acid in fructose-induced metabolic syndromeAm J Physiol Renal Physiol20062903F625F63116234313
   PubMed Web of Science ®Google Scholar
• SaglamFCelikASariogluSHyperuricemia influences chronic cyclosporine nephropathyTransplant Proc200840116717018261576
   PubMed Web of Science ®Google Scholar
• WhiteMHaddadHLeblancMHConversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsionJ Heart Lung Transplant200524779880915982605
   PubMed Web of Science ®Google Scholar
• NoordzijTCLeunissenKMvan HooffJPRenal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic useTransplantation199152164671858156
   PubMed Web of Science ®Google Scholar
• NakagawaTTuttleKRShortRAJohnsonRJHypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndromeNat Clin Pract Nephrol200512808616932373
   PubMedGoogle Scholar
• Sanchez-LozadaLGTapiaEBautista-GarciaPEffects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndromeAm J Physiol Renal Physiol20082944F710F71818216151
   PubMed Web of Science ®Google Scholar
• SiuYPLeungKTTongMKKwanTHUse of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid levelAm J Kidney Dis2006471515916377385
   PubMed Web of Science ®Google Scholar
• WhiteJSMisconceptions about high-fructose corn syrup: is it uniquely responsible for obesity, reactive dicarbonyl compounds, and advanced glycation endproducts?J Nutr200913961219S1227S19386820
   PubMed Web of Science ®Google Scholar
• WhiteJSStraight talk about high-fructose corn syrup: what it is and what it ain’tAm J Clin Nutr20088861716S1721S19064536
   PubMed Web of Science ®Google Scholar
• SoleimaniMDietary fructose, salt absorption and hypertension in metabolic syndrome: Toward a new paradigmActa Physiol (Oxf)2010 [Epub ahead of print]
   Web of Science ®Google Scholar
• AkhavanTAndersonGHEffects of glucose-to-fructose ratios in solutions on subjective satiety, food intake, and satiety hormones in young menAm J Clin Nutr20078651354136317991646
   PubMed Web of Science ®Google Scholar
• FesselWJRenal outcomes of gout and hyperuricemiaAm J Med19796717482463920
   PubMed Web of Science ®Google Scholar
• Miranda-CarusEMateosFASanzAGHerreroERamosTPuigJGPurine metabolism in patients with gout: the role of leadNephron19977533273359069456
   PubMed Web of Science ®Google Scholar
• FeigDIUric acid: a novel mediator and marker of risk in chronic kidney disease?Curr Opin Nephrol Hypertens200918652653019654543
   PubMed Web of Science ®Google Scholar
• EdwardsNLThe role of hyperuricemia in vascular disordersCurr Opin Rheumatol200921213213719339923
   PubMed Web of Science ®Google Scholar
• KangDHHanLOuyangXUric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporterAm J Nephrol200525542543316113518
   PubMed Web of Science ®Google Scholar
• NakagawaTMazzaliMKangDHHyperuricemia causes glomerular hypertrophy in the ratAm J Nephrol20032312712373074
   PubMed Web of Science ®Google Scholar
• NakagawaTKangDHOhashiRTubulointerstitial disease: role of ischemia and microvascular diseaseCurr Opin Nephrol Hypertens200312323324112698060
   PubMed Web of Science ®Google Scholar
• GibsonTRodgersVPotterCSimmondsHAAllopurinol treatment and its effect on renal function in gout: a controlled studyAnn Rheum Dis198241159657039523
   PubMed Web of Science ®Google Scholar
• AvramZKrishnanEHyperuricaemia – where nephrology meets rheumatologyRheumatology (Oxford)200847796096418443007
   PubMed Web of Science ®Google Scholar
• WheltonAMacDonaldPLloydELademacherCBeneficial relationship of serum urate (sUA) reduction and estimated glomerular filtration rate (eGFR) improvement/maintenance in hyperuricemic gout subjects treated for up to 5.5 years with febuxostat (FEB) [abstract)2008 American College of Rheumatology MeetingSan Francisco, CA2008
   Google Scholar
• GaffoALEdwardsNLSaagKGGout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?Arthritis Res Ther200911424019725932
   PubMed Web of Science ®Google Scholar
• ShahAKeenanRTGout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?Curr Rheumatol Rep201012211812420425020
   PubMedGoogle Scholar
• RoncalCAReungjuiSSanchez-LozadaLGCombination of captopril and allopurinol retards fructose-induced metabolic syndromeAm J Nephrol200930539940419696478
   PubMed Web of Science ®Google Scholar
• NakagawaTMazzaliMKangDHSanchez-LozadaLGHerrera-AcostaJJohnsonRJUric acid – a uremic toxin?Blood Purif2006241677016361844
   PubMed Web of Science ®Google Scholar
• MasuoKKawaguchiHMikamiHOgiharaTTuckMLSerum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevationHypertension200342447448012953019
   PubMed Web of Science ®Google Scholar
• NagahamaKInoueTIsekiKHyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, JapanHypertens Res2004271183584115824465
   PubMed Web of Science ®Google Scholar
• NakanishiNOkamotoMYoshidaHMatsuoYSuzukiKTataraKSerum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workersEur J Epidemiol200318652353012908717
   PubMed Web of Science ®Google Scholar
• AnnemansLSpaepenEGaskinMGout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005Ann Rheum Dis200867796096617981913
   PubMed Web of Science ®Google Scholar
• KrishnanEKwohCKSchumacherHRKullerLHyperuricemia and incidence of hypertension among men without metabolic syndromeHypertension200749229830317190877
   PubMed Web of Science ®Google Scholar
• FeigDISoletskyBJohnsonRJEffect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trialJAMA2008300892493218728266
   PubMed Web of Science ®Google Scholar
• TangZChengLTLiHYWangTSerum uric acid and endothelial dysfunction in continuous ambulatory peritoneal dialysis patientsAm J Nephrol200929536837318974637
   PubMed Web of Science ®Google Scholar
• BergaminiCCicoiraMRossiAVassanelliCOxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failureEur J Heart Fail200911544445219346534
   PubMed Web of Science ®Google Scholar
• MitsuhashiHYatsuyaHMatsushitaKUric acid and left ventricular hypertrophy in Japanese menCirc J200973466767219225200
   PubMed Web of Science ®Google Scholar
• BainbridgeSAvon Versen-HoynckFRobertsJMUric acid inhibits placental system A amino acid uptakePlacenta200930219520019058847
   PubMed Web of Science ®Google Scholar
• TerkeltaubRBushinskyDABeckerMARecent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeuticsArthritis Res Ther20068Suppl 1S416820043
   PubMed Web of Science ®Google Scholar
• BenedictJDForshamPHStettenDJrThe metabolism of uric acid in the normal and gouty human studied with the aid of isotopic uric acidJ Biol Chem1949181118319315390405
   PubMed Web of Science ®Google Scholar
• CampoCRuilopeLMSeguraJRodicioJLGarcia-RoblesRGarcia-PuigJHyperuricemia, low urine urate excretion and target organ damage in arterial hypertensionBlood Press2003125–627728314763658
   PubMed Web of Science ®Google Scholar
• EnomotoAKimuraHChairoungduaAMolecular identification of a renal urate anion exchanger that regulates blood urate levelsNature2002417688744745212024214
   PubMed Web of Science ®Google Scholar
• EralySAVallonVRiegTMultiple organic anion transporters contribute to net renal excretion of uric acidPhysiol Genomics200833218019218270321
   PubMed Web of Science ®Google Scholar
• SilvermanWLocoveiSDahlGProbenecid, a gout remedy, inhibits pannexin 1 channelsAm J Physiol Cell Physiol20082953C761C76718596212
   PubMed Web of Science ®Google Scholar
• EnomotoANiwaTKanaiYEndouHUrate transporter and renal hypouricemiaRinsho Byori200351989289714560659
   PubMedGoogle Scholar
• SoAThorensBUric acid transport and diseaseJ Clin Invest201012061791179920516647
   PubMed Web of Science ®Google Scholar
• LipkowitzMSLeal-PintoECohenBEAbramsonRGGalectin 9 is the sugar-regulated urate transporter/channel UATGlycoconj J2004197–949149814758072
   PubMed Web of Science ®Google Scholar
• ChoiHKZhuYMountDBGenetics of goutCurr Opin Rheumatol201022214415120110790
   PubMed Web of Science ®Google Scholar
• UranoWTaniguchiAAnzaiNSodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with goutAnn Rheum Dis20106961232123419556210
   PubMed Web of Science ®Google Scholar
• MatsuoHTakadaTIchidaKCommon defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese populationSci Transl Med2009155ra11
   PubMed Web of Science ®Google Scholar
• CheesemanCSolute carrier family 2, member 9 and uric acid homeostasisCurr Opin Nephrol Hypertens200918542843219593129
   PubMed Web of Science ®Google Scholar
• DahanKDevuystOSmaersMA cluster of mutations in the UMOD gene causes familial juvenile hyperuricemic nephropathy with abnormal expression of uromodulinJ Am Soc Nephrol200314112883289314569098
   PubMed Web of Science ®Google Scholar
• RampoldiLCaridiGSantonDAllelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamicsHum Mol Genet200312243369338414570709
   PubMed Web of Science ®Google Scholar
• StoreyGDAlfred Baring Garrod (1819–1907)Rheumatology (Oxford)200140101189119011600751
   PubMed Web of Science ®Google Scholar
• FairesJSMcCartyDJAcute arthritis in man and dog after intrasynovial injection of sodium urate crystalsLancet19622807258682685
   Google Scholar
• PascualEJovaniVA quantitative study of the phagocytosis of urate crystals in the synovial fluid of asymptomatic joints of patients with goutBr J Rheumatol19953487247267551655
   PubMedGoogle Scholar
• SimkinPAConcentration of urate by differential diffusion: a hypothesis for initial urate depositionAdv Exp Med Biol1974415475504832580
   PubMedGoogle Scholar
• SoADevelopments in the scientific and clinical understanding of goutArthritis Res Ther200810522118947374
   PubMed Web of Science ®Google Scholar
• PillingerMHKeenanRTUpdate on the management of hyperuricemia and goutBull NYU Hosp Jt Dis200866323123918937638
   PubMedGoogle Scholar
• LioteFEaHKRecent developments in crystal-induced inflammation pathogenesis and managementCurr Rheumatol Rep20079324325017531179
   PubMedGoogle Scholar
• ReginatoAMOlsenBRGenetics and experimental models of crystal-induced arthritis. Lessons learned from mice and men: is it crystal clear?Curr Opin Rheumatol200719213414517278928
   PubMed Web of Science ®Google Scholar
• RoseDMLiu-BryanRInnate immunity in triggering and resolution of acute gouty inflammationCurr Rheumatol Rep20068320921416901079
   PubMedGoogle Scholar
• KoopmanWJMorelandLWArthritis and Allied Conditions: A Textbook of Rheumatology15th edPhiladelphiaLippincott Williams & Wilkins2005
   Google Scholar
• AbramsonSHoffsteinSTWeissmannGSuperoxide anion generation by human neutrophils exposed to monosodium urateArthritis Rheum19822521741806279115
   PubMed Web of Science ®Google Scholar
• TerkeltaubRADyerCAMartinJCurtissLKApolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivoJ Clin Invest199187120261985096
   PubMed Web of Science ®Google Scholar
• AkahoshiTMurakamiYKitasatoHRecent advances in crystal-induced acute inflammationCurr Opin Rheumatol200719214615017278929
   PubMed Web of Science ®Google Scholar
• McCartyDJJrPhelpsPPyensonJCrystal-induced inflammation in canine joints. I. An experimental model with quantification of the host responseJ Exp Med19661241991144287616
   PubMed Web of Science ®Google Scholar
• FalascaGFRamachandrulaAKelleyKAO’ConnorCRReginatoAJSuperoxide anion production and phagocytosis of crystals by cultured endothelial cellsArthritis Rheum19933611051168381009
   PubMed Web of Science ®Google Scholar
• TerkeltaubRZachariaeCSantoroDMartinJPeveriPMatsushimaKMonocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammationArthritis Rheum19913478949032059236
   PubMed Web of Science ®Google Scholar
• DuffGWAtkinsEMalawistaSEThe fever of gout: urate crystals activate endogenous pyrogen production from human and rabbit mononuclear phagocytesTrans Assoc Am Physicians1983962342456093311
   PubMedGoogle Scholar
• MartinWJWaltonMHarperJResident macrophages initiating and driving inflammation in a monosodium urate monohydrate crystal-induced murine peritoneal model of acute goutArthritis Rheum200960128128919116939
   PubMed Web of Science ®Google Scholar
• MartinWJHarperJLInnate inflammation and resolution in acute goutImmunol Cell Biol2010881151919935764
   PubMed Web of Science ®Google Scholar
• Liu-BryanRScottPSydlaskeARoseDMTerkeltaubRInnate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammationArthritis Rheum20055292936294616142712
   PubMed Web of Science ®Google Scholar
• RyckmanCGilbertCde MedicisRLussierAVandalKTessierPAMonosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophilsJ Leukoc Biol200476243344015107458
   PubMed Web of Science ®Google Scholar
• GassePRiteauNCharronSUric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosisAm J Respir Crit Care Med20091791090391319218193
   PubMed Web of Science ®Google Scholar
• MartinonFMayorATschoppJThe inflammasomes: guardians of the bodyAnnu Rev Immunol20092722926519302040
   PubMed Web of Science ®Google Scholar
• BianchiMEDAMPs, PAMPs and alarmins: all we need to know about dangerJ Leukoc Biol20078111517032697
   PubMed Web of Science ®Google Scholar
• MalawistaSEDuffGWAtkinsECheungHSMcCartyDJCrystal-induced endogenous pyrogen production. A further look at gouty inflammationArthritis Rheum1985289103910462994686
   PubMed Web of Science ®Google Scholar
• WoodDDIhrieEJDinarelloCACohenPLIsolation of an interleukin-1-like factor from human joint effusionsArthritis Rheum19832689759836603852
   PubMed Web of Science ®Google Scholar
• di GiovineFSMalawistaSENukiGDuffGWInterleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1J Immunol198751513810321332183033070
   PubMed Web of Science ®Google Scholar
• MartinonFBurnsKTschoppJThe inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-betaMol Cell200210241742612191486
   PubMed Web of Science ®Google Scholar
• MartinonFPetrilliVMayorATardivelATschoppJGout-associated uric acid crystals activate the NALP3 inflammasomeNature2006440708123724116407889
   PubMed Web of Science ®Google Scholar
• SidiropoulosPIGoulielmosGVoloudakisGKPetrakiEBoumpasDTInflammasomes and rheumatic diseases: evolving conceptsAnn Rheum Dis200867101382138917921182
   PubMed Web of Science ®Google Scholar
• FranchiLEigenbrodTMunoz-PlanilloRNunezGThe inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesisNat Immunol200910324124719221555
   PubMed Web of Science ®Google Scholar
• PopeRMTschoppJThe role of interleukin-1 and the inflammasome in gout: implications for therapyArthritis Rheum200756103183318817907163
   PubMed Web of Science ®Google Scholar
• Liu-BryanRIntracellular innate immunity in gouty arthritis: role of NALP3 inflammasomeImmunol Cell Biol2010881202319935768
   PubMed Web of Science ®Google Scholar
• ChurchLDCookGPMcDermottMFPrimer: inflammasomes and interleukin 1beta in inflammatory disordersNat Clin Pract Rheumatol200841344218172447
   PubMedGoogle Scholar
• PetrilliVMartinonFThe inflammasome, autoinflammatory diseases, and goutJoint Bone Spine200774657157617714972
   PubMed Web of Science ®Google Scholar
• Liu-BryanRPritzkerKFiresteinGSTerkeltaubRTLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generationJ Immunol200517485016502315814732
   PubMed Web of Science ®Google Scholar
• Liu-BryanRLioteFMonosodium urate and calcium pyrophosphate dihydrate (CPPD) crystals, inflammation, and cellular signalingJoint Bone Spine200572429530215990350
   PubMed Web of Science ®Google Scholar
• ScottPMaHViriyakosolSTerkeltaubRLiu-BryanREngagement of CD14 mediates the inflammatory potential of monosodium urate crystalsJ Immunol200617796370637817056568
   PubMed Web of Science ®Google Scholar
• YagnikDREvansBJFloreyOMasonJCLandisRCHaskardDOMacrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammationArthritis Rheum20045072273228015248227
   PubMed Web of Science ®Google Scholar
• LandisRCYagnikDRFloreyOSafe disposal of inflammatory monosodium urate monohydrate crystals by differentiated macrophagesArthritis Rheum200246113026303312428246
   PubMed Web of Science ®Google Scholar
• MarcolongoRCalabriaAALalumeraMGerliRAlessandriniCCavalloGThe “switch-off ” mechanism of spontaneous resolution of acute gout attackJ Rheumatol19881511011092832599
   PubMed Web of Science ®Google Scholar
• SchumacherHRJrThe pathogenesis of goutCleve Clin J Med200875Suppl 5S2S418822468
   PubMedGoogle Scholar
• FalascaGFMetabolic diseases: goutClin Dermatol200624649850817113968
   PubMed Web of Science ®Google Scholar
• ter BorgEJRaskerJJGout in the elderly, a separate entity?Ann Rheum Dis198746172763813677
   PubMed Web of Science ®Google Scholar
• O’DellJRGout in Heberden’s nodesArthritis Rheum19832611141314146639700
   PubMed Web of Science ®Google Scholar
• Molinos NormiellaCRey GalanCMedina VillanuevaAConcha TorreAMenendez CuervoSUric acid as a prognostic marker in critically ill patientsAn Esp Pediatr200155430530911578536
   PubMedGoogle Scholar
• WeaverJSomaniNBauerTWPiliangMSimple non-staining method to demonstrate urate crystals in formalin-fixed, paraffin-embedded skin biopsiesJ Cutan Pathol200936556056419476524
   PubMed Web of Science ®Google Scholar
• ShidhamVChivukulaMBasirZShidhamGEvaluation of crystals in formalin-fixed, paraffin-embedded tissue sections for the differential diagnosis of pseudogout, gout, and tumoral calcinosisMod Pathol200114880681011504841
   PubMed Web of Science ®Google Scholar
• Perez-RuizFDalbethNUrresolaAde MiguelESchlesingerNImaging of gout: findings and utilityArthritis Res Ther200911323219591633
   PubMed Web of Science ®Google Scholar
• DalbethNMcQueenFMUse of imaging to evaluate gout and other crystal deposition disordersCurr Opin Rheumatol200921212413119339922
   PubMed Web of Science ®Google Scholar
• FilippucciEScireCADelle SedieAUltrasound imaging for the rheumatologist. XXV. Sonographic assessment of the knee in patients with gout and calcium pyrophosphate deposition diseaseClin Exp Rheumatol20102812520346230
   PubMed Web of Science ®Google Scholar
• de Avila FernandesEKubotaESSandimGBMitraudSAFerrariAJFernandesARUltrasound features of tophi in chronic tophaceous goutSkeletal Radiol2010 [Epub ahead of print]
   Web of Science ®Google Scholar
• ThieleRGSchlesingerNDiagnosis of gout by ultrasoundRheumatology (Oxford)20074671116112117468505
   PubMed Web of Science ®Google Scholar
• CarterJDKedarRPAndersonSRAn analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographsRheumatology (Oxford)200948111442144619745028
   PubMed Web of Science ®Google Scholar
• KunkelGKaeleyGThieleRComment on: an analysis of MRI and ultrasound imaging in patients with gout who have normal plain radiographsRheumatology (Oxford)201049510221023 author reply1023102420172992
   PubMed Web of Science ®Google Scholar
• NeogiTHunterDJChaissonCEAllensworth-DaviesDZhangYFrequency and predictors of inappropriate management of recurrent gout attacks in a longitudinal studyJ Rheumatol200633110410916267879
   PubMed Web of Science ®Google Scholar
• TerkeltaubRAFurstDEBennettKKookKACrockettRSDavisMWHigh versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine studyArthritis Rheum20106241060106820131255
   PubMed Web of Science ®Google Scholar
• PharmaUColcrys Official Prescribing Information20105 Official Prescribing Information. http://colcrys.com/assets/pdf/COLCRYS_Full_Prescribing_Information.pdf. Accessed 2010 Aug 28.
   Google Scholar
• MoladYUpdate on colchicine and its mechanism of actionCurr Rheumatol Rep20024325225612010611
   PubMedGoogle Scholar
• ChenYJHuangSMLiuCYYehPHTsaiTHHepatobiliary excretion and enterohepatic circulation of colchicine in ratsInt J Pharm20083501–223023917931809
   PubMed Web of Science ®Google Scholar
• MontsenyJJMeyrierAGherardiRKColchicine toxicity in patients with chronic renal failureNephrol Dial Transplant19961110205520588918722
   PubMed Web of Science ®Google Scholar
• SchiffDDrislaneFWRapid-onset colchicine myoneuropathyArthritis Rheum19923512153515361472131
   PubMed Web of Science ®Google Scholar
• FiehnCZeierMSuccessful treatment of chronic tophaceous gout with infliximab (Remicade)Rheumatol Int200626327427615933855
   PubMed Web of Science ®Google Scholar
• TauscheAKRichterKGrasslerAHanselSRochBSchroderHESevere gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic optionAnn Rheum Dis200463101351135215361402
   PubMed Web of Science ®Google Scholar
• MengZHHudsonAPSchumacherHRJrBakerJFBakerDGMonosodium urate, hydroxyapatite, and calcium pyrophosphate crystals induce tumor necrosis factor-alpha expression in a mononuclear cell lineJ Rheumatol19972412238523889415647
   PubMed Web of Science ®Google Scholar
• di GiovineFSMalawistaSEThorntonEDuffGWUrate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distributionJ Clin Invest1991874137513812010550
   PubMed Web of Science ®Google Scholar
• SoAde SmedtTRevazSTschoppJA pilot study of IL-1 inhibition by anakinra in acute goutArthritis Res Ther200792R2817352828
   PubMed Web of Science ®Google Scholar
• SinghDHustonKKIL-1 inhibition with anakinra in a patient with refractory goutJ Clin Rheumatol200915736620009976
   PubMed Web of Science ®Google Scholar
• GrattonSBScalapinoKJFyeKHCase of anakinra as a steroid-sparing agent for gout inflammationArthritis Rheum20096191268127019714614
   PubMed Web of Science ®Google Scholar
• TerkeltaubRSundyJSSchumacherHRThe interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot studyAnn Rheum Dis200968101613161719635719
   PubMed Web of Science ®Google Scholar
• SoAde MeulemeesterMPikhlakACanakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging studyArthritis Rheum201062103064307620533546
   PubMed Web of Science ®Google Scholar
• Study of Tranilast Alone or in Combination With Allopurinol in Subjects With Hyperuricemia. 2010; http://clinicaltrials.gov/ct2/show/NCT01052987?intr=Tranilast&rank=2. Accessed 2010 Sep 1.
   Google Scholar
• HiggsGIs PDE4 too difficult a drug target?Curr Opin Investig Drugs2010115495498
   Google Scholar
• Apremilast Therapy for Acute Gouty Arthritis2010 http://clinicaltrials.gov/ct2/show/NCT00997581?term=apremilast&rank=11. Accessed 2010 Sep 1.
   Google Scholar
• FavreLGlassonPRiondelAVallottonMBInteraction of diuretics and non-steroidal anti-inflammatory drugs in manClin Sci (Lond)19836444074156337769
   PubMed Web of Science ®Google Scholar
• FavreLGlassonPVallottonMBReversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjectsAnn Intern Med19829633173206949485
   PubMed Web of Science ®Google Scholar
• VarugheseGIVargheseAIColchicine myoneuropathy: the role of rhabdomyolysisNephrology (Carlton)2006115481482 author reply 48217014570
   PubMed Web of Science ®Google Scholar
• LaiICChengCYChenHHChenWYChenPYColchicine myoneuropathy in chronic renal failure patients with goutNephrology (Carlton)200611214715016669978
   PubMed Web of Science ®Google Scholar
• KunclRWDuncanGWatsonDAldersonKRogawskiMAPeperMColchicine myopathy and neuropathyN Engl J Med198731625156215683035372
   PubMed Web of Science ®Google Scholar
• Uloric Full Prescribing Information2009 http://general.takedapharm.com/content/file/pi.pdf?applicationcode=6C7C39D8-5D09-453B-BF30-696A4AB88E62&FileTypeCode=ULORICPI. Accessed 2010 Aug 30.
   Google Scholar
• KissinEYNishioJYangMSelf-directed learning of basic musculoskeletal ultrasound among rheumatologists in the United StatesArthritis Care Res (Hoboken)201062215516020191513
   PubMed Web of Science ®Google Scholar
• FilippucciERiverosMGGeorgescuDSalaffiFGrassiWHyaline cartilage involvement in patients with gout and calcium pyrophosphate deposition disease. An ultrasound studyOsteoarthritis Cartilage200917217818118657999
   PubMed Web of Science ®Google Scholar
• ChoiHKA prescription for lifestyle change in patients with hyperuricemia and goutCurr Opin Rheumatol201022216517220035225
   PubMed Web of Science ®Google Scholar
• DohertyMNew insights into the epidemiology of goutRheumatology (Oxford)200948Suppl 2ii2ii819447779
   PubMed Web of Science ®Google Scholar
• CutlerDMGlaeserELShapiroJMWhy have Americans become more obese?J Econ Perspect20031793118
   Web of Science ®Google Scholar
• Statistics Related to Overweight and Obesity NIH Publication Number 04-4158. 2010; http://win.niddk.nih.gov/statistics/. Accessed 2010 Aug 1.
   Google Scholar
• ChoiHKAtkinsonKKarlsonEWCurhanGObesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up studyArch Intern Med2005165774274815824292
   PubMed Web of Science ®Google Scholar
• ChoiJWFordESGaoXChoiHKSugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The Third National Health and Nutrition Examination SurveyArthritis Rheum200859110911618163396
   PubMed Web of Science ®Google Scholar
• ChoiHKCurhanGSoft drinks, fructose consumption, and the risk of gout in men: prospective cohort studyBMJ2008336763930931218244959
   PubMed Web of Science ®Google Scholar
• SchlesingerNDietary factors and hyperuricaemiaCurr Pharm Des200511324133413816375734
   PubMed Web of Science ®Google Scholar
• KerndtPRNaughtonJLDriscollCELoxterkampDAFasting: the history, pathophysiology and complicationsWest J Med198213753793996758355
   PubMedGoogle Scholar
• ChoiHKAtkinsonKKarlsonEWWillettWCurhanGAlcohol intake and risk of incident gout in men: a prospective studyLancet200436394171277128115094272
   PubMed Web of Science ®Google Scholar
• JacobRASpinozziGMSimonVAConsumption of cherries lowers plasma urate in healthy womenJ Nutr200313361826182912771324
   PubMed Web of Science ®Google Scholar
• HowatsonGMcHughMPHillJAInfluence of tart cherry juice on indices of recovery following marathon runningScand J Med Sci Sports2009 [Epub ahead of print]
   Google Scholar
• KelleyDSRasoolyRJacobRAKaderAAMackeyBEConsumption of Bing sweet cherries lowers circulating concentrations of inflammation markers in healthy men and womenJ Nutr2006136498198616549461
   PubMed Web of Science ®Google Scholar
• USDA National Nutrient Database for Standard Reference. Nutrient Data Laboratory Home Page, http://www.ars.usda.gov/ba/bhnrc/ndl. US Department of Agriculture; 2010. http://www.ars.usda.gov/ba/bhnrc/ndl. Accessed 2010 Oct 8.
   Google Scholar
• BlauLWCherry diet control for gout and arthritisTex Rep Biol Med19508330931114776685
   PubMedGoogle Scholar
• SteinHBHasanAFoxIHAscorbic acid-induced uricosuria. A consequency of megavitamin therapyAnn Intern Med19768443853881259282
   PubMed Web of Science ®Google Scholar
• ChoiHKGaoXCurhanGVitamin C intake and the risk of gout in men: a prospective studyArch Intern Med2009169550250719273781
   PubMedGoogle Scholar
• GaoXCurhanGFormanJPAscherioAChoiHKVitamin C intake and serum uric acid concentration in menJ Rheumatol20083591853185818464304
   PubMed Web of Science ®Google Scholar
• McGillNWGout and other crystal-associated arthropathiesBaillieres Best Pract Res Clin Rheumatol200014344546010985980
   PubMed Web of Science ®Google Scholar
• SarawateCABrewerKKYangWGout medication treatment patterns and adherence to standards of care from a managed care perspectiveMayo Clin Proc200681792593416835972
   PubMed Web of Science ®Google Scholar
• RiedelAANelsonMWallaceKJoseph-RidgeNClearyMFamAGPrevalence of Comorbid Conditions and Prescription Medication Use Among Patients With Gout and Hyperuricemia in a Managed Care SettingJ Clin Rheumatol200410630831417043538
   PubMed Web of Science ®Google Scholar
• RiedelAANelsonMJoseph-RidgeNWallaceKMacDonaldPBeckerMCompliance with allopurinol therapy among managed care enrollees with gout: a retrospective analysis of administrative claimsJ Rheumatol20043181575158115290738
   PubMed Web of Science ®Google Scholar
• ReindersMKHaagsmaCJansenTLA randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with goutAnn Rheum Dis200968689289718633127
   PubMed Web of Science ®Google Scholar
• DalbethNStampLAllopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse eventsSemin Dial200720539139517897242
   PubMed Web of Science ®Google Scholar
• ShalomRRimbrothSRozenmanDMarkelAAllopurinol-induced recurrent DRESS syndrome: pathophysiology and treatmentRen Fail200830332732918350453
   PubMed Web of Science ®Google Scholar
• FamAGLewtasJSteinJPatonTWDesensitization to allopurinol in patients with gout and cutaneous reactionsAm J Med19929332993021388001
   PubMed Web of Science ®Google Scholar
• LeeSSLinHYWangSRTsaiYYAllopurinol hypersensitivity syndromeZhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi19942731401479747344
   PubMedGoogle Scholar
• LuptonGPOdomRBThe allopurinol hypersensitivity syndromeJ Am Acad Dermatol197914365374159913
   PubMed Web of Science ®Google Scholar
• RoujeauJCKellyJPNaldiLMedication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysisN Engl J Med199533324160016077477195
   PubMed Web of Science ®Google Scholar
• MarkelAAllopurinol-induced DRESS syndromeIsr Med Assoc J200571065666016259349
   PubMed Web of Science ®Google Scholar
• HungSIChungWHLiouLBHLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinolProc Natl Acad Sci U S A2005102114134413915743917
   PubMed Web of Science ®Google Scholar
• Zyloprim® Official Prescribing Information. 2003; http://www.prometheuspatients.com/PDF/Zyloprim.pdf. Accessed 2010 Aug 30.
   Google Scholar
• ChaoJTerkeltaubRA critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in goutCurr Rheumatol Rep200911213514019296886
   PubMedGoogle Scholar
• GaffoALSaagKGManagement of hyperuricemia and gout in CKDAm J Kidney Dis2008525994100918971014
   PubMed Web of Science ®Google Scholar
• MurrellGARapeportWGClinical pharmacokinetics of allopurinolClin Pharmacokinet19861153433533536254
   PubMed Web of Science ®Google Scholar
• HandeKRNooneRMStoneWJSevere allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiencyAm J Med198476147566691361
   PubMed Web of Science ®Google Scholar
• BellamyNGilbertJRBrooksPMEmmersonBTCampbellJA survey of current prescribing practices of antiinflammatory and urate lowering drugs in gouty arthritis in the province of OntarioJ Rheumatol19881512184118473265960
   PubMed Web of Science ®Google Scholar
• DalbethNKumarSStampLGowPDose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with goutJ Rheumatol20063381646165016783857
   PubMed Web of Science ®Google Scholar
• Vazquez-MelladoJMoralesEMPacheco-TenaCBurgos-VargasRRelation between adverse events associated with allopurinol and renal function in patients with goutAnn Rheum Dis2001601098198311557658
   PubMed Web of Science ®Google Scholar
• IfuduOTanCCDulinALDelanoBGFriedmanEAGouty arthritis in end-stage renal disease: clinical course and rarity of new casesAm J Kidney Dis19942333473518128934
   PubMed Web of Science ®Google Scholar
• SchreinerOWandelEHimmelsbachFGallePRMarker-HermannEReduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients?Nephrol Dial Transplant200015564464910809805
   PubMed Web of Science ®Google Scholar
• GargJPChasan-TaberSBlairAEffects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trialArthritis Rheum200552129029515641045
   PubMed Web of Science ®Google Scholar
• StampLHaLSearleMO’DonnellJFramptonCChapmanPGout in renal transplant recipientsNephrology (Carlton)200611436737116889578
   PubMed Web of Science ®Google Scholar
• StampLSearleMO’DonnellJChapmanPGout in solid organ transplantation: a challenging clinical problemDrugs200565182593261116392875
   PubMed Web of Science ®Google Scholar
• Siegenthaler-ZuberGWhich uric acid value is in need of treatment?Schweiz Med Wochenschr1976106144874911265467
   PubMedGoogle Scholar
• LiangMHFriesJFAsymptomatic hyperuricemia: the case for conservative managementAnn Intern Med1978885666670646260
   PubMed Web of Science ®Google Scholar
• DawsonJQuinnTWaltersMUric acid reduction: a new paradigm in the management of cardiovascular risk?Curr Med Chem200714171879188617627523
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRJrWortmannRLFebuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with goutArthritis Rheum200552391692315751090
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRJrWortmannRLFebuxostat compared with allopurinol in patients with hyperuricemia and goutN Engl J Med2005353232450246116339094
   PubMed Web of Science ®Google Scholar
• Febuxostat Phase 3 Clinical Trials Study NCT00174915. Takeda Pharmaceuticals; 2009. http://clinicaltrials.gov/ct2/show/results/NCT00174915?term=gout&rank=9&sect=X6015#outcome1. Accessed 2010 Jun 21.
   Google Scholar
• TerkeltaubRAClinical practice. GoutN Engl J Med2003349171647165514573737
   PubMed Web of Science ®Google Scholar
• ReindersMKvan RoonENJansenTLEfficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinolAnn Rheum Dis2009681515618250112
   PubMed Web of Science ®Google Scholar
• LeeMHGrahamGGWilliamsKMDayROA benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?Drug Saf200831864366518636784
   PubMed Web of Science ®Google Scholar
• TakahashiSMoriwakiYYamamotoTTsutsumiZKaTFukuchiMEffects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolismAnn Rheum Dis200362657257512759298
   PubMed Web of Science ®Google Scholar
• TerkeltaubRGout. Novel therapies for treatment of gout and hyperuricemiaArthritis Res Ther23200911423619664185
   PubMed Web of Science ®Google Scholar
• LaskoBSheedyBHingoraniVRDEA594, a novel uricosuric agent, significantly reduced serum urate levels and was well tolerated in a phase 2a pilot study in hyperuricemic gout patients2009 American College of Rheumatology Annual Scientific MeetingPhiladelphia, PA2009
   Google Scholar
• Ardea Biosciences Announces positive results from a Phase 1 Study of RDEA594Medical News Today2009 http://www.medicalnewstoday.com/articles/135285.php. Accessed 2010 Aug 30.
   Google Scholar